- Home
- BMY vs SNY Comparison
BMY vs SNY Comparison
Compare BMY & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMY | SNY |
|---|---|---|
| Founded | 1887 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.5B | 104.5B |
| IPO Year | 2006 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BMY | SNY |
|---|---|---|
| Price | $63.73 | $42.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $61.73 | $58.00 |
| AVG Volume (30 Days) | ★ 7.0M | 2.0M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.38% | 3.47% |
| EPS Growth | ★ 178.46 | N/A |
| EPS | ★ 2.93 | N/A |
| Revenue | ★ $48,194,000,000.00 | N/A |
| Revenue This Year | N/A | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | $21.72 | ★ $6.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $42.52 | $40.89 |
| 52 Week High | $68.64 | $52.68 |
Technical Indicators
Market Signals| Indicator | BMY | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 45.24 |
| Support Level | $63.00 | $43.28 |
| Resistance Level | $68.33 | $45.22 |
| Average True Range (ATR) | 1.13 | 0.55 |
| MACD | -0.56 | -0.25 |
| Stochastic Oscillator | 31.79 | 30.22 |
Price Performance
Historical ComparisonAbout BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.